Interestingly, metformin, an oral agent commonly prescribed to treat type 2 diabetes involved in the reduction of hepatic glucose production and/or insulin resistance, has shown to also decrease plasma DPP IV activity, limiting the inactivation of exogenously administered peptides [84]. Here, INS is linked to type 2 diabetes mellitus.